CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Saxagliptin

Saxagliptin

Last Updated: May 28, 2012

Result type: Reports

Project Number: SR0280-000

Product Line: Reimbursement Review

Generic Name: Saxagliptin

Brand Name: Onglyza

Manufacturer: Bristol-Myers Squibb / AstraZeneca Canada Inc.

Therapeutic Area: Diabetes mellitus, type 2

Indications: Diabetes mellitus (Type 2)

Submission Type: Resubmission

Project Status: Withdrawn

Saxagliptin

Files